What is ENPATORAN used for?

ENPATORAN is being studied for potential use in treating COVID-19, lupus, and dermatomyositis.

Is ENPATORAN approved for use?

No, ENPATORAN is currently an experimental drug in clinical trial phases.

Can ENPATORAN treat systemic lupus erythematosus?

Researchers are currently investigating if ENPATORAN can help treat systemic lupus erythematosus.

Is ENPATORAN being tested for COVID-19?

Yes, ENPATORAN is being researched for its effects on COVID-19.

What kind of drug is ENPATORAN?

ENPATORAN is classified as a small molecule research compound.

What is dermatomyositis?

Dermatomyositis is one of the medical conditions being studied in relation to ENPATORAN.

Enpatoran | CAS 2101938-42-3 | BJXYHBKEQFQVES

Loading compound...

Small molecule research compound

ENPATORAN is an experimental small molecule drug currently being studied in clinical trials. It is being researched for its potential use in treating conditions such as COVID-19, systemic lupus erythematosus, dermatomyositis, and cutaneous lupus erythematosus.

How it worksThe specific biological mechanism of ENPATORAN is not yet publicly detailed in the provided data.

Used for

COVID-19dermatomyositissystemic lupus erythematosuscutaneous lupus erythematosus

Conditions

COVID-19dermatomyositissystemic lupus erythematosuscutaneous lupus erythematosus

Class

Small moleculeSmall molecule research compound

How to take

This drug is currently in the research phase (Phase 1 and Phase 2) and is not yet approved for general use by regulatory agencies.

Talk to your doctor

Questions to ask

·Is ENPATORAN part of any clinical trials I can join?
·How does ENPATORAN differ from current lupus treatments?

Educational summary derived from FDA labeling, AI-assisted. Not medical advice — consult a healthcare professional. Updated 2026-04-25.

How to take

Talk to your doctor

Frequently asked questions (6)